Clinical Trial Record

Return to Clinical Trials

A Phase I Trial of Gemcitabine and Radiation in Locally Advanced Unresectable Cancer of the Pancreas


1995-02


N/A


2000-11


20

Study Overview

A Phase I Trial of Gemcitabine and Radiation in Locally Advanced Unresectable Cancer of the Pancreas

Radiotherapy plus Single-Agent Chemotherapy/Radiosensitization. Involved-field irradiation using 4-15 MV photons; plus Gemcitabine, NSC-613327.

This is a Phase I trial of gemcitabine given weekly as a 30 minute infusion administered concurrently with radiation in patients with locally advanced or locally recurrent pancreatic carcinoma. Patients will be treated with external beam radiation therapy in a standard manner. Gemcitabine will be administered as a 30 minute infusion beginning on the first day of irradiation and weekly afterwards for a total of 5 doses. Patients will be assessed clinically for acute toxicity which will be graded per RTOG and DCT toxicity grading system.

  • Gastrointestinal Neoplasms
  • Pancreatic Neoplasms
  • DRUG: gemcitabine
  • 950075
  • 95-C-0075

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates Results Reporting Dates Study Record Updates

1999-11-03  

N/A  

2008-03-03  

2002-12-09  

N/A  

2008-03-04  

2002-12-10  

N/A  

2000-11  

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
Treatment


Allocation:
N/A


Interventional Model:
N/A


Masking:
N/A


Arms and Interventions

Participant Group/ArmIntervention/Treatment
Secondary Outcome MeasuresMeasure DescriptionTime Frame

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:

Accepts Healthy Volunteers:

    DISEASE CHARACTERISTICS:
    Histologically or cytologically proven unresectable adenocarcinoma of the pancreas or ampulla of Vater. Surgical consult at NCI confirming unresectability fulfills requirement.
    Unresectable disease defined as tumor with: Gross involvement of regional nodes or direct extension to any of the following sites: Duodenum, Spleen, Bile duct , Colon, Peripancreatic tissue, Adjacent large vessels, Stomach.
    Metastatic disease requiring local radiotherapy allowed. No CNS metastasis.
    No lymphomas or neuroendocrine tumors.
    No peritoneal carcinomatosis.
    PRIOR/CONCURRENT THERAPY:
    Biologic Therapy: More than 4 weeks since immunotherapy.
    Chemotherapy:
    No prior chemotherapy for newly diagnosed disease.
    More than 4 weeks since chemotherapy for recurrent disease (6 weeks since nitrosoureas, mitomycin, or suramin).
    Endocrine Therapy: More than 4 weeks since hormonal therapy.
    Radiotherapy:
    No prior radiotherapy for newly diagnosed disease.
    No prior abdominal or pelvic radiotherapy.
    More than 4 weeks since radiotherapy for recurrent disease. No prior radiotherapy for locally advanced disease after resection allowed.
    Surgery:
    Prior resection allowed.
    Biliary decompression or gastric bypass allowed.
    PATIENT CHARACTERISTICS:
    Age: 18 and over.
    Performance status: ECOG 0-2.
    Hematopoietic:
    ANC greater than 2,000/mm(3).
    Platelets greater than 100,000/mm(3).
    Hepatic: AST/ALT no greater than 2.5 times normal.
    Renal:
    Creatinine less than 1.5 mg/dL.
    Creatinine clearance at least 60 mL/min,
    Cardiovascular:
    No myocardial infarction within 6 months.
    No unstable angina.
    No congestive heart failure (NYHA class III/IV).
    OTHER:
    HIV seronegative.
    No medical or psychiatric contraindication to protocol therapy.
    No concurrent malignancy other than: Skin cancer, Cervical carcinoma in situ.
    No pregnant or nursing women.
    Adequate contraception required of fertile patients.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

  • Morohoshi T, Held G, Kloppel G. Exocrine pancreatic tumours and their histological classification. A study based on 167 autopsy and 97 surgical cases. Histopathology. 1983 Sep;7(5):645-61. doi: 10.1111/j.1365-2559.1983.tb02277.x.
  • Rosenberg JM, Welch JP, Macaulay WP. Cancer of the head of the pancreas: an institutional review with emphasis on surgical therapy. J Surg Oncol. 1985 Mar;28(3):217-21. doi: 10.1002/jso.2930280315.